KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Gains from Sales and Divestitures: 2010-2011

  • Vertex Pharmaceuticals' Gains from Sales and Divestitures rose 37.32% to $747,000 in Q4 2011 from the same period last year, while for Dec 2011 it was $747,000, marking a year-over-year increase of 37.32%. This contributed to the annual value of $747,000 for FY2011, which is 37.32% up from last year.
  • Per Vertex Pharmaceuticals' latest filing, its Gains from Sales and Divestitures stood at $747,000 for Q4 2011, which was up 37.32% from $544,000 recorded in Q4 2010.
  • In the past 5 years, Vertex Pharmaceuticals' Gains from Sales and Divestitures registered a high of $747,000 during Q4 2011, and its lowest value of $544,000 during Q4 2010.
  • In the last 2 years, Vertex Pharmaceuticals' Gains from Sales and Divestitures had a median value of $645,500 in 2010 and averaged $645,500.
  • Data for Vertex Pharmaceuticals' Gains from Sales and Divestitures shows a peak YoY skyrocketed of 37.32% (in 2011) over the last 5 years.
  • Over the past 2 years, Vertex Pharmaceuticals' Gains from Sales and Divestitures (Quarterly) stood at $544,000 in 2010, then skyrocketed by 37.32% to $747,000 in 2011.